An independent source of information on U.S. brand name drugs for health professionals

Drugdocs Logo

An independent source of information on U.S. brand name drugs for health professionals

HomeDrugsGlossaryAboutContact Us

Menu

HomeDrugsGlossaryAboutContact Us

Drugs A-Z

ABCDE FGHIJKLMNOPQRSTUVWXYZ

DRUGS

A

B

C

D

E

F

G

H

I

J

K

L

M

N

O

P

Q

R

S

T

U

V

W

X

Y

Z

Fluorodopa F 18

Chemical NameFluorodopa F 18
Dosage FormInjectable (intravenous; 15.5 MBq/mL to 308.2 MBq/mL (0.42 mCi/mL to 8.33 mCi/mL))
Drug ClassRadioactive diagnostic agents
SystemNervous
CompanyFeinstein
Approval Year2019

Indication

  • Fluorodopa F 18 is indicated for use in positron emission tomography (PET) to visualize dopaminergic nerve terminals in the striatum for the evaluation of adult patients with suspected Parkinsonian syndromes (PS). Fluorodopa F 18 PET is an adjunct to other diagnostic evaluations.
Last updated on 1/12/2021

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Fluorodopa F 18 Prescribing Information 2019Feinstein
Document TitleYearSource
Diagnostic performance and prognostic value of PET/CT with different tracers for brain tumors: a systematic review of published meta-analyses. 2019International Journal of Molecular Sciences
Accuracy of 18 F-FDOPA positron emission tomography and 18 F-FET positron emission tomography for differentiating radiation necrosis from brain tumor recurrence. 2018World Neurosurgery
A systematic review of lessons learned from PET molecular imaging research in atypical parkinsonism. 2016European Journal of Nuclear Medicine and Molecular Imaging
Conventional and nuclear medicine imaging in ectopic Cushing’s syndrome: a systematic review. 2015The Journal of Clinical Endocrinology & Metabolism
The incremental benefit of functional imaging in pheochromocytoma/paraganglioma: a systematic review. 2015Endocrine